Gorlin's syndrome is an autosomal dominant disorder, mainly characterized by the presence of multiple and early-onset basal cell carcinomas, odontogenic keratocysts and palmoplantar pits. We describe the case of a patient with clinical and imaging features of Gorlin syndrome, and highlight the role of dermoscopy in the early detection of basal cell carcinomas. In addition, we discuss the dermoscopic features of palmar pits.
Gorlin's syndrome is an autosomal dominant disorder, mainly characterized by the presence of multiple and early-onset basal cell carcinomas, odontogenic keratocysts and palmoplantar pits. We describe the case of a patient with clinical and imaging features of Gorlin syndrome, and highlight the role of dermoscopy in the early detection of basal cell carcinomas. In addition, we discuss the dermoscopic features of palmar pits.
Gorlin's syndrome (GS) or nevoid basal cell carcinoma syndrome is an autosomal dominant
disorder caused by mutations in PTC, the human homologue of the
Drosophilapatched gene. This condition has a variable phenotypic
expression, probably due to the interaction of genetic and environmental factors. Common
features include the presence of multiple and early-onset basal cell carcinomas (BCC),
odontogenic keratocysts (OKC) of the jaw, palmoplantar pits, broad forehead, rib
anomalies, calcified falx cerebri, and other developmental anomalies and neoplasms.[1]
CASE REPORT
A 50-year-old female with a history of uterine fibroma (UF) and right cheek BCC excised
26 and 7 years before, respectively, presented for the evaluation of 3 nodular lesions
on the face, which were clinically suggestive of BCC. Additionally, she reported
frequent back pain and exhibited multiple milia scattered over her face, coarse facies
with hypertelorism and prognathism, and mild palmar pitting (Figure 1). Attentive skin examination and dermoscopy disclosed a
total of 8 lesions suggestive of BCCs. The most commonly observed dermoscopy features
were: arborizing vessels, ulceration, blue-gray globules and spoke-wheel areas (Figure 2). Dermoscopy also enabled a better
visualization of the palmar pits, and revealed flesh-colored, irregular-shaped and
slightly depressed lesions, some of them with red globules inside (Figure 3). The patient's mother had died at the age of 65 years due
to destructive BCC of the periorbital area. Her 26-year-old daughter had a history of
OKC of the jaw and UF excised at the ages of 17 and 19 years, respectively; 3 facial
BCCs, the first having been removed at 19 years of age; hypertelorism; prognathism;
milia on the face and severe palmar pits (Figure
4). Two of the proband's brothers had also underwent excision of multiple BCCs
since their 4th decade of life. Imaging studies (skull, face, chest and spine
X-ray and CT scan) disclosed calcification of the cerebral falx, OKC of the left jaw,
bilateral bifid ribs, marked dextroconvex dorsal scoliosis associated with hemivertebra,
and prominent transverse processes of C7 (Figure
5). ECG, abdomino-pelvic US and ophthalmological examination were normal. Based
on the clinical and radiological features, and the family history, our patient was
diagnosed as having a familial GS. The facial tumors were excised, and the diagnosis of
BCC was confirmed histologically in all lesions included in this study.
FIGURE 1
Patient’s clinical appearance. Three nodular basal cell carcinomas (arrows),
multiple milia (c) and coarse facies with hypertelorism and
prognathism (d,e)
FIGURE 2
Dermosco - pic features of some basal cell carcinomas. Arborizing vessels
(asterisks), ulceration (white arrows), bluegray globules (head arrow) and
spokewheel areas (black arrow)
FIGURE 3
Dermoscopic features of palmar pitting. Flesh-colored, irregular-shaped and
slightly depressed lesions, some with red globules
FIGURE 4
Patient’s daughter’s clinical appearance. Hypertelorism (line), prognathism
(head arrow), milia (asterisks) and severe palmar pits (arrows)
FIGURE 5
Radiological findings. (a) Calcifi cation of the cerebral falx,
(b) odontogenic keratocysts of the maxilla, (c) bifi
d ribs, and (d) marked dextroconvex dorsal scoliosis (arrow)
associated with hemivertebra (head arrow)
Patient’s clinical appearance. Three nodular basal cell carcinomas (arrows),
multiple milia (c) and coarse facies with hypertelorism and
prognathism (d,e)Dermosco - pic features of some basal cell carcinomas. Arborizing vessels
(asterisks), ulceration (white arrows), bluegray globules (head arrow) and
spokewheel areas (black arrow)Dermoscopic features of palmar pitting. Flesh-colored, irregular-shaped and
slightly depressed lesions, some with red globulesPatient’s daughter’s clinical appearance. Hypertelorism (line), prognathism
(head arrow), milia (asterisks) and severe palmar pits (arrows)Radiological findings. (a) Calcifi cation of the cerebral falx,
(b) odontogenic keratocysts of the maxilla, (c) bifi
d ribs, and (d) marked dextroconvex dorsal scoliosis (arrow)
associated with hemivertebra (head arrow)
DISCUSSION
The clinical diagnosis of GS is based on the presence of multiple BCCs and palmoplantar
pits, in association with internal abnormalities and skeletal defects. With dermoscopy,
BCCs in GS can be detected in early stages by the presence of typical, but often subtle,
dermoscopic features of BCC. Acral pits, which are often overlooked during physical
examination, have a characteristic dermoscopy and can be easily visualized with this
tool.[2],[3] Additionally, the role of dermoscopy in predicting tumor subtype
has been demonstrated, and this may influence the choice of treatment. Maple leaf-like
areas, short fine superficial telangiectasia, multiple small erosions, and shiny
white-red structureless areas seem to be potent predictors of superficial BCC, while the
presence of arborizing vessels, blue-gray ovoid nests, and ulceration increases the
possibility of the diagnosis of non-superficial BCCs.[4]Although sporadic human BCC are generally well managed with excisional surgery,
considering the number and characteristic recurrent nature of the lesions in GS, several
alternative approaches have been used - alone or in combination -, including ablative
laser therapy, electrocoagulation, cryosurgery, photo-dynamic therapy, topical imiquimod
and 5-fluorouracil.[5] Unfortunately, there are no
large-scale studies on the treatment of BCCs in this syndrome. The choice of treatment
is generally based on a combination of factors, which include: available clinical
evidence, patient and tumor characteristics, patient's choice, local availability of
specialized services, and experience and preferences of the physician. The development
of an oral hedgehog pathway inhibitor, vismodegib, has raised a new dimension to the
current treatment of BCCs. The recent demonstration that vismodegib additionally shrinks
some OKCs in patients with GS will surely increase the interest in the drug when
treating patients with this syndrome.[6]This case was unusual in that the patient presented with most of the clinical and
imaging criteria for diagnosing GS, as defined by Kimonis et al..[1] The decision to surgically excise the BCCs was
based on several factors, such as clinical and dermoscopy features predicting
non-superficial subtype in most of the lesions, the patient's will, the availability of
technics, and the experience and preference of the specialist physician involved.We intend to emphasize that a regular dermatological examination is recommended for all
patients with GS, so that BCCs can be early diagnosed and treated. A continuous and
multidisciplinary approach, as well as a follow-up are essential, given the diverse
clinical manifestations patients can present through-out life. These recommendations
might help avoid possible complications and thus improve quality of life.
Authors: Danica Tiodorovic-Zivkovic; Iris Zalaudek; Gerardo Ferrara; Caterina M Giorgio; Karin Di Nola; Enrico M Procaccini; Giuseppe Argenziano Journal: J Am Acad Dermatol Date: 2010-10 Impact factor: 11.527
Authors: Mina S Ally; Jean Y Tang; Timmy Joseph; Bobbye Thompson; Joselyn Lindgren; Maria Acosta Raphael; Grace Ulerio; Anita M Chanana; Julian M Mackay-Wiggan; David R Bickers; Ervin H Epstein Journal: JAMA Dermatol Date: 2014-05 Impact factor: 10.282